XYLAC SOLUTION

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Składnik aktywny:

LOXAPINE (LOXAPINE HYDROCHLORIDE)

Dostępny od:

PENDOPHARM DIVISION OF PHARMASCIENCE INC

Kod ATC:

N05AH01

INN (International Nazwa):

LOXAPINE

Dawkowanie:

25MG

Forma farmaceutyczna:

SOLUTION

Skład:

LOXAPINE (LOXAPINE HYDROCHLORIDE) 25MG

Droga podania:

ORAL

Sztuk w opakowaniu:

100

Typ recepty:

Prescription

Dziedzina terapeutyczna:

MISCELLANEOUS ANTIPSYCHOTICS

Podsumowanie produktu:

Active ingredient group (AIG) number: 0111557001; AHFS:

Status autoryzacji:

CANCELLED POST MARKET

Data autoryzacji:

2020-07-17

Charakterystyka produktu

PRODUCT MONOGRAPH
PR XYLAC
TM
Loxapine Succinate Tablets
2.5, 5, 10, 25 & 50 mg
Loxapine Hydrochloride Solution
Oral Concentrate 25 mg/mL
Antipsychotic
ATC Code: N05AH01
PENDOPHARM, DIVISION OF PHARMASCIENCE INC.
6111 Royalmount Ave, Suite 100
Montréal, Canada
H4P 2T4
Date of Preparation:
May 15, 2012
Control No: 155424
TM
Trademark of Pharmascience Inc.
_XYLAC_
_TM_
_ Product Monograph Page 1 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 2
SUMMARY PRODUCT INFORMATION
........................................................................
2
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
3
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
10
DOSAGE AND ADMINISTRATION
.............................................................................
13
OVERDOSAGE
................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 15
STORAGE AND STABILITY
.........................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 16
PART II: SCIENTIFIC INFORMATION
..............................................................................
19
PHARMACEUTICAL INFORMATION
.........................................................................
19
CLINICAL TRIALS
.............................................................................